Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
grade F 13.74 -1.51% -0.21
INVA closed down 1.51 percent on Friday, March 22, 2019, on 68 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical INVA trend table...

Date Alert Name Type % Chg
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Oversold Stochastic Weakness -1.51%
Mar 20 Stochastic Reached Oversold Weakness -1.36%
Mar 20 Oversold Stochastic Weakness -1.36%
Mar 19 1,2,3 Retracement Bearish Bearish Swing Setup -2.97%
Mar 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.97%
Mar 18 Inside Day Range Contraction -3.10%
Mar 15 Outside Day Range Expansion -2.97%
Mar 14 NR7 Range Contraction -2.83%
Mar 13 Shooting Star Candlestick Bearish -3.65%

Older signals for INVA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.
Medicine Drugs Glucocorticoids Organofluorides
Is INVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.54
52 Week Low 13.26
Average Volume 1,225,081
200-Day Moving Average 15.5292
50-Day Moving Average 16.1956
20-Day Moving Average 14.596
10-Day Moving Average 14.094
Average True Range 0.487
ADX 37.61
+DI 11.7016
-DI 30.2366
Chandelier Exit (Long, 3 ATRs ) 14.829
Chandelier Exit (Short, 3 ATRs ) 15.081
Upper Bollinger Band 16.0548
Lower Bollinger Band 13.1372
Percent B (%b) 0.21
BandWidth 19.989038
MACD Line -0.5531
MACD Signal Line -0.5852
MACD Histogram 0.0321
Fundamentals Value
Market Cap 1.5 Billion
Num Shares 109 Million
EPS 0.80
Price-to-Earnings (P/E) Ratio 17.18
Price-to-Sales 7.61
Price-to-Book 0.00
PEG Ratio 0.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.36
Resistance 3 (R3) 14.40 14.24 14.25
Resistance 2 (R2) 14.24 14.08 14.22 14.22
Resistance 1 (R1) 13.99 13.99 13.91 13.95 14.18
Pivot Point 13.83 13.83 13.79 13.81 13.83
Support 1 (S1) 13.58 13.67 13.50 13.54 13.30
Support 2 (S2) 13.42 13.58 13.40 13.26
Support 3 (S3) 13.17 13.42 13.23
Support 4 (S4) 13.13